IGC Pharma, Inc.

Stage 1 · Basing · week 8

As of Oct 22, 2026, IGC Pharma is in Stage 1, the basing phase, now in week 8 (since Sep 2, 2026). It closed at $0.25, 40.5% below its 52-week high and below its 200-day average, which is falling.

$0.25

+14.00% today

$25.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is IGC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 20w

S2 15w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 5w → S3 1w → S4 19w → S1 4w → S2 12w → S3 13w → S4 9w → S1 5w → S4 20w → S1 10w → S2 15w → S3 6w → S4 16w → S1 10w → S4 9w → S1 7w current

Total tracked: 166 weeks across 17 stage runs.

IGC among Biotechnology303rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…303	IGCIGC Pharma, Inc.	Stage 1 · wk 8	30	−13.8%

vs 52W High

-40.5%

$0.22 lo$0.42 hi

40.5% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 8

1w13w26w

Week 8, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-11.4%

200 DMA: $0.28 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.22x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.8%

-3.8%

-26.5%

YTD

-13.8%

-35.9%

Scan Membership

Breakout Watch

Latest: 2024-04-02

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 8 · Vol 0.22x

2026-10-21S1

Wk 7 · Vol 0.48x

2026-10-20S1

Wk 7 · Vol 0.53x

2026-10-19S1

Wk 7 · Vol 0.65x

2026-10-16S1

Wk 7 · Vol 0.49x

2026-10-15S1

Wk 7 · Vol 0.95x

2026-10-14S1

Wk 6 · Vol 1.17x

2026-10-13S1

Wk 6 · Vol 0.52x

2026-10-12S1

Wk 6 · Vol 0.72x

2026-10-09S1

Wk 6 · Vol 0.29x

2026-10-08S1

Wk 6 · Vol 0.77x

2026-10-07S1

Wk 5 · Vol 0.38x

Moving averages & range

50 DMA

$0.28

200 DMA

$0.28

52W High

$0.42

52W Low

$0.22

5D Low

$0.22

Resistance levels (recent highs)

20d High

$0.28

60d High

$0.33

120d High

$0.33

250d High

$0.42

Next resistance

+12.0%

to 20d High

ROE

-83.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 4.1

IGC Pharma: quick answers

What stage is IGC Pharma in?

As of Oct 22, 2026, IGC Pharma (IGC) is in Stage 1, the basing phase. It entered Stage 1 on Sep 2, 2026 and is in week 8. What the four stages mean

Is IGC Pharma in an uptrend?

Not yet. IGC Pharma is in Stage 1, a base that can come before an uptrend. It trades 11.4% below its 200-day average, which is falling.

How far is IGC Pharma from its 52-week high?

IGC Pharma closed at $0.25 on Oct 22, 2026, 40.5% below its 52-week high of $0.42. Its 52-week low is $0.22.

How has IGC Pharma performed over the past year?

As of Oct 22, 2026, IGC Pharma is down 35.9% over the past year and down 13.8% so far in 2026.

Which sector and industry is IGC Pharma in?

IGC Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.